Norland Medical Systems
This article was originally published in The Gray Sheet
Executive Summary
Firm is able to market its entire line of bone densitometers with a fracture risk feature following FDA clearance to include the feature on its Eclipse and XR-36 DXA central bone densitometers and its SCT2000 peripheral bone densitometer. Clearance of the technology for use on the three systems is the latest in a series received by the company; in February the firm's pDEXA peripheral forearm bone densitometer became the first densitometer to gain FDA clearance for use in predicting fracture risk, and in May Norland gained the same clearance for its Apollo DXA peripheral heel bone system...